[go: up one dir, main page]

EP1610776A2 - Compositions ophtalmiques pour traiter une hypertension oculaire - Google Patents

Compositions ophtalmiques pour traiter une hypertension oculaire

Info

Publication number
EP1610776A2
EP1610776A2 EP04758273A EP04758273A EP1610776A2 EP 1610776 A2 EP1610776 A2 EP 1610776A2 EP 04758273 A EP04758273 A EP 04758273A EP 04758273 A EP04758273 A EP 04758273A EP 1610776 A2 EP1610776 A2 EP 1610776A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
heterocyclyl
aryl
methoxy
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04758273A
Other languages
German (de)
English (en)
Other versions
EP1610776A4 (fr
Inventor
Michael H. Fisher
Maria L. Garcia
Gregory J. Kaczorowski
Peter T. Meinke
William H. Parsons
Edward Andrew Boyd
Stephen Price
John Stibbard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec OAI
Merck and Co Inc
Original Assignee
Evotec OAI
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec OAI, Merck and Co Inc filed Critical Evotec OAI
Publication of EP1610776A2 publication Critical patent/EP1610776A2/fr
Publication of EP1610776A4 publication Critical patent/EP1610776A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • R w represents H, Ci -6 alkyl, -C(O)Ci_6 alkyl, -C(O)OCi-6 alkyl, -SO2N(R)2, -SO2C1-6 alkyl, -SO2C6-IO aryl, N0 2 , CN or -C(O)N(R)2;
  • R2 and R3 taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R a ;
  • R6 represents hydrogen, Ci-io alkyl, -(CH2) n C6-10 aryl, -NH(CH2) n C6-10 aryl, -(CH2) n C5-10 heteroaryl, -NH(CH2) n C5-10 heteroaryl, (C ⁇ -lO aryl)O-, -(CH2) n C3-10 heterocyclyl, -(CH2)nC3-8 cycloalkyl, -COOR, -C(O)C02R, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from Ra;
  • R8 represents -(CH2) n C3-8 cycloalkyl, -(CH2)n 3-10 heterocyclyl, Ci-6 alkoxy or -(CH2) n C5- 10 heteroaryl, -(CH2)nC6-10 aryl said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;
  • Still another embodiment of this invention is realized when Y is -CO(CH2)n, Q is N, R2 is Ci-io alkyl or C ⁇ _ alkylOH and R3 is (CH2)nC3-lO heterocyclyl, said heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R a .
  • a subembodiment of this invention is realized when n is 0.
  • physostigmine has the drawback of being considerably limited by its short half-life of effect, poor oral bioavailability, and severe dose-limiting side-effects, particularly towards the digestive system.
  • Tacrine tetrahydroaminocridine
  • salts of the compounds of formula I will be pharmaceutically acceptable salts.
  • Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
  • suitable “pharmaceutically acceptable salts” refers to salts prepared form pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
  • the pharmaceutical preparation which contains the compound may be conveniently admixed with a non-toxic pharmaceutical organic carrier, or with a non-toxic pharmaceutical inorganic carrier.
  • a non-toxic pharmaceutical organic carrier or with a non-toxic pharmaceutical inorganic carrier.
  • pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or aralkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethyl-cellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally employed acceptable carriers.
  • Step A N-methanesulfonly-l-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetamide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de bloqueurs puissants de canaux de potassium ou une formulation de ceux-ci pour le traitement du glaucome et d'autres troubles menant à une pression intra-oculaire élevée dans l'oeil d'un patient. L'invention concerne également l'utilisation de tels composés pour produire un effet neuroprotecteur sur l'oeil d'espèces mammifères, en particulier chez les humains.
EP04758273A 2003-03-27 2004-03-24 Compositions ophtalmiques pour traiter une hypertension oculaire Withdrawn EP1610776A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45810303P 2003-03-27 2003-03-27
PCT/US2004/009028 WO2004087051A2 (fr) 2003-03-27 2004-03-24 Compositions ophtalmiques pour traiter une hypertension oculaire

Publications (2)

Publication Number Publication Date
EP1610776A2 true EP1610776A2 (fr) 2006-01-04
EP1610776A4 EP1610776A4 (fr) 2007-03-28

Family

ID=33131753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04758273A Withdrawn EP1610776A4 (fr) 2003-03-27 2004-03-24 Compositions ophtalmiques pour traiter une hypertension oculaire

Country Status (7)

Country Link
US (1) US7414067B2 (fr)
EP (1) EP1610776A4 (fr)
JP (1) JP2006524239A (fr)
CN (1) CN1791402A (fr)
AU (1) AU2004226479A1 (fr)
CA (1) CA2519899A1 (fr)
WO (1) WO2004087051A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523363A (ja) * 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のための二環式複素芳香族アミド化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
BR6570394D0 (pt) * 1964-07-02 1973-08-14 Merck & Co Inc Processo para a preparacao de compostos da serie indolica
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
US3669960A (en) * 1968-09-10 1972-06-13 Sumitomo Chemical Co Novel amides of 3-indolylacetic acid
IT7920398A0 (it) * 1979-02-21 1979-02-21 Resfar Srl Derivato ad attivita' analgesica antiinfiammatoria potenziata eprocedimento per la sua preparazione.
US4416890A (en) * 1981-07-13 1983-11-22 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4386098A (en) * 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4426388A (en) * 1982-04-02 1984-01-17 Merck & Co., Inc. 5-Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4668697A (en) * 1983-10-31 1987-05-26 Merck & Co., Inc. Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
JP2844593B2 (ja) * 1987-05-28 1999-01-06 ソニー株式会社 受信装置
ATE108330T1 (de) * 1987-09-18 1994-07-15 R Tech Ueno Ltd Hypotensive okulare mittel.
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
US4943587A (en) 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
WO1994028900A1 (fr) 1993-06-08 1994-12-22 Vide Pharmaceuticals Procedes et comositions d'abaissement de la pression intra-oculaire
FI963272A0 (fi) * 1994-02-22 1996-08-21 Merrell Pharma Inc Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
BR0013143A (pt) * 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
ATE409491T1 (de) * 2000-01-18 2008-10-15 Merck & Co Inc Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
CA2406383A1 (fr) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Agents de reduction de a.beta.42
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof

Also Published As

Publication number Publication date
AU2004226479A1 (en) 2004-10-14
CA2519899A1 (fr) 2004-10-14
JP2006524239A (ja) 2006-10-26
US20060069256A1 (en) 2006-03-30
EP1610776A4 (fr) 2007-03-28
US7414067B2 (en) 2008-08-19
WO2004087051A2 (fr) 2004-10-14
CN1791402A (zh) 2006-06-21
WO2004087051A3 (fr) 2005-07-21

Similar Documents

Publication Publication Date Title
US20060148805A1 (en) Opthalmic compositions for treating ocular hypertension
WO2007108968A2 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
US7528163B2 (en) Ophthalmic compositions for treating ocular hypertension
HRP20050409A2 (en) Ophthalmic compositions for treating ocular hypertension
AU2005295831A1 (en) Ophthalmic compositions for treating ocular hypertension
AU2003239972B2 (en) Ophthalmic compositions for treating ocular hypertension
EP2032130A2 (fr) Compositions ophtalmiques pour traiter une hypertension oculaire
US7563816B2 (en) Ophthalmic compositions for treating ocular hypertension
AU2004272546B2 (en) Ophthalmic compositions for treating ocular hypertension
US7414067B2 (en) Ophthalmic compositions for treating ocular hypertension
AU2004271978B2 (en) Ophthalmic compositions for treating ocular hypertension
US20080097108A1 (en) Ophthalmic Compositions for Treating Ocular Hypertension

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20060123

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060123

Extension state: LT

Payment date: 20060123

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060123

Extension state: LT

Payment date: 20060123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20070109BHEP

Ipc: C07D 209/04 20060101ALI20070109BHEP

Ipc: A61K 31/404 20060101ALI20070109BHEP

Ipc: C07D 209/28 20060101AFI20070109BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070223

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STIBBARD, JOHN

Inventor name: PRICE, STEPHEN

Inventor name: BOYD, EDWARD ANDREW

Inventor name: PARSONS, WILLIAM, H.

Inventor name: MEINKE, PETER, T.

Inventor name: KACZOROWSKI, GREGORY, J.

Inventor name: GARCIA, MARIA, L.

Inventor name: FISHER, MICHAEL, H.

17Q First examination report despatched

Effective date: 20071106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090113